Guardant Health (NASDAQ:GH) Reaches New 12-Month Low at $28.32

Guardant Health, Inc. (NASDAQ:GH – Get Rating) shares hit a new 52-week low during trading on Thursday . The company traded as low as $28.32 and last traded at $28.82, with a volume of 2713668 shares traded. The stock had previously closed at $31.33.

A number of equities analysts recently weighed in on GH shares. Zacks Investment Research lowered shares of Guardant Health from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Wells Fargo & Company decreased their price objective on shares of Guardant Health from $150.00 to $115.00 and set an “overweight” rating for the company in a report on Thursday, February 24th. SVB Leerink decreased their target price on shares of Guardant Health from $170.00 to $140.00 and set an “outperform” rating for the company in a research note on Thursday, February 24th. Morgan Stanley decreased their target price on shares of Guardant Health from $125.00 to $120.00 and set an “overweight” rating for the company in a research note on Thursday, February 24th. Finally, Cowen reduced their price objective on Guardant Health from $170.00 to $110.00 and set an “outperform” rating for the company in a research note on Thursday, February 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus price target of $136.83.

The company’s 50 day moving average price is $60.19 and its 200 day moving average price is $78.11. The company has a quick ratio of 4.71, a current ratio of 4.87 and a debt-to-equity ratio of 2.13. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of -8.72 and a beta of 0.70.

Guardant Health (NASDAQ:GH – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($1.21) EPS for the quarter, hitting the consensus estimate of ($1.21). Guardant Health had a negative net margin of 107.20% and a negative return on equity of 62.68%. The business had revenue of $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. During the same period in the previous year, the firm posted ($1.06) earnings per share. The business’s revenue for the quarter was up 22.2% compared to the same quarter last year. As a group, analysts expect that Guardant Health, Inc. will post -4.76 earnings per share for the current year.

In other Guardant Health news, Director Stanley J. Meresman sold 4,934 shares of Guardant Health stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $58.74, for a total value of $289,823.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in GH. Confluence Wealth Services Inc. acquired a new position in Guardant Health during the fourth quarter worth about $29,000. Hall Laurie J Trustee acquired a new position in Guardant Health during the fourth quarter worth about $30,000. National Bank of Canada FI acquired a new position in Guardant Health during the fourth quarter worth about $32,000. FourThought Financial LLC boosted its holdings in Guardant Health by 1,690.0% in the 3rd quarter. FourThought Financial LLC now owns 358 shares of the company’s stock valued at $44,000 after purchasing an additional 338 shares during the last quarter. Finally, Pinebridge Investments L.P. acquired a new position in Guardant Health in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 93.69% of the company’s stock.

Guardant Health Company Profile (NASDAQ:GH)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Articles